VHT Stock Overview
Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand.
Volpara Health Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.53|
|52 Week High||AU$1.32|
|52 Week Low||AU$0.40|
|1 Month Change||-13.82%|
|3 Month Change||26.19%|
|1 Year Change||-55.46%|
|3 Year Change||-67.58%|
|5 Year Change||-15.87%|
|Change since IPO||6.00%|
Recent News & Updates
|VHT||AU Healthcare Services||AU Market|
Return vs Industry: VHT underperformed the Australian Healthcare Services industry which returned -19.6% over the past year.
Return vs Market: VHT underperformed the Australian Market which returned -10.6% over the past year.
|VHT Average Weekly Movement||11.3%|
|Healthcare Services Industry Average Movement||11.5%|
|Market Average Movement||9.6%|
|10% most volatile stocks in AU Market||16.7%|
|10% least volatile stocks in AU Market||4.3%|
Stable Share Price: VHT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: VHT's weekly volatility (11%) has been stable over the past year.
About the Company
Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand. The company offers Volpara Analytics, a software that optimize breast cancer screening operations; Volpara Live, which provides instant patient-based image quality feedback; Volpara Lung, a patient management software that streamlines lung screening workflow; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses TC8 to calculate patients’ risk of developing breast cancer; Volpara Risk Pathways, a program for identifying and managing high-risk breast cancer screening patients; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products.
Volpara Health Technologies Fundamentals Summary
|VHT fundamental statistics|
Is VHT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VHT income statement (TTM)|
|Cost of Revenue||NZ$2.29m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.065|
|Net Profit Margin||-62.96%|
How did VHT perform over the long term?See historical performance and comparison
Is VHT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VHT?
Other financial metrics that can be useful for relative valuation.
|What is VHT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does VHT's PS Ratio compare to its peers?
|VHT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
M7T Mach7 Technologies
ALC Alcidion Group
VHT Volpara Health Technologies
Price-To-Sales vs Peers: VHT is good value based on its Price-To-Sales Ratio (5.8x) compared to the peer average (13.7x).
Price to Earnings Ratio vs Industry
How does VHT's PE Ratio compare vs other companies in the AU Healthcare Services Industry?
Price-To-Sales vs Industry: VHT is expensive based on its Price-To-Sales Ratio (5.8x) compared to the Australian Healthcare Services industry average (5x)
Price to Sales Ratio vs Fair Ratio
What is VHT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||5.8x|
|Fair PS Ratio||11.1x|
Price-To-Sales vs Fair Ratio: VHT is good value based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (11.1x).
Share Price vs Fair Value
What is the Fair Price of VHT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VHT (A$0.53) is trading below our estimate of fair value (A$1.09)
Significantly Below Fair Value: VHT is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Volpara Health Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VHT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: VHT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VHT is expected to become profitable in the next 3 years.
Revenue vs Market: VHT's revenue (22% per year) is forecast to grow faster than the Australian market (3.7% per year).
High Growth Revenue: VHT's revenue (22% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VHT's Return on Equity is forecast to be low in 3 years time (0.4%).
Discover growth companies
How has Volpara Health Technologies performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VHT is currently unprofitable.
Growing Profit Margin: VHT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VHT is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare VHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VHT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (2.7%).
Return on Equity
High ROE: VHT has a negative Return on Equity (-28.4%), as it is currently unprofitable.
Discover strong past performing companies
How is Volpara Health Technologies's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VHT's short term assets (NZ$30.4M) exceed its short term liabilities (NZ$20.9M).
Long Term Liabilities: VHT's short term assets (NZ$30.4M) exceed its long term liabilities (NZ$2.2M).
Debt to Equity History and Analysis
Debt Level: VHT has more cash than its total debt.
Reducing Debt: VHT's debt to equity ratio has increased from 0.03% to 0.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VHT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if VHT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Volpara Health Technologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Volpara Health Technologies Dividend Yield vs Market|
|Company (Volpara Health Technologies)||n/a|
|Market Bottom 25% (AU)||2.8%|
|Market Top 25% (AU)||7.2%|
|Industry Average (Healthcare Services)||0.6%|
|Analyst forecast in 3 Years (Volpara Health Technologies)||0%|
Notable Dividend: Unable to evaluate VHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VHT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VHT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Teri Thomas is Chief Executive Officer of Volpara Health Technologies Limited from April 2022. She served as an Executive Vice President of Global Sales, Marketing & Strategy at Orion Health Group Limi...
Experienced Management: VHT's management team is considered experienced (2.8 years average tenure).
Experienced Board: VHT's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VHT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|29 Jun 22||BuyAU$28,610||John Pavlidis||Individual||69,100||AU$0.41|
|22 Jun 22||BuyAU$13,500||John Diddams||Individual||30,000||AU$0.45|
|17 Jun 22||BuyAU$2,020,226||Harbour Asset Management Limited||Company||3,266,525||AU$0.62|
|16 Jun 22||BuyAU$16,801||John Diddams||Individual||30,001||AU$0.56|
|15 Jun 22||BuyAU$66,959||Paul Robert Reid||Individual||115,000||AU$0.58|
|10 May 22||SellAU$415,905||Harbour Asset Management Limited||Company||541,280||AU$0.77|
|23 Mar 22||BuyAU$3,306,802||Harbour Asset Management Limited||Company||3,553,098||AU$0.93|
|09 Mar 22||SellAU$1,046,884||Harbour Asset Management Limited||Company||964,153||AU$1.09|
|13 Dec 21||SellAU$493||First NZ Capital Ltd., Asset Management Arm||Company||500||AU$0.99|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Volpara Health Technologies Limited's employee growth, exchange listings and data sources
- Name: Volpara Health Technologies Limited
- Ticker: VHT
- Exchange: ASX
- Founded: 2009
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: AU$123.504m
- Shares outstanding: 252.05m
- Website: https://www.volparahealth.com
Number of Employees
- Volpara Health Technologies Limited
- Simpl House
- Level 14
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VHT||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Apr 2016|
|VHT||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Apr 2016|
|VPAH.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Apr 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.